You know the saying 'you wait ages for a bus, and then 2 arrive at once'. Well the same analogy can be applied to the DDI regulatory guidance. Not only did the FDA released a new draft in October, the Japanese PMDA also updated their guidance a few weeks earlier. Many of the updates are consistent between the regulatory authorities but there are some subtle differences. To capture the differences we have updated our popular 'Everything you need to know about ADME' guide. Our 'DDI regulatory guidance - An easy to follow guide' has also been revised to reflect the FDA updates. These guides are now available to download online.
To complement the recent DDI updates, Evotec's Dr Beth Williamson and Dr Rob Riley have authored a publication in Expert Opinion on Drug Metabolism and Toxicology. The publication compares and contrasts different static models for predicting hepatic transporter DDI, and provides recommendations as to their application.
This month, Cyprotex also attended the IVTS meeting in London. Head of Toxicology at our UK facility, Dr Paul Walker, had a speaking slot at the event and presented on 'The development and characterisation of 3D neuronal microtissues for safety testing'. Find out more below and download the slides.
You may also be interested in a number of Evotec webinars held recently.
- Neuroprotective Treatment Strategies in Multiple Sclerosis
- Therapeutic Strategies for Harnessing the Immune System against Cancer
- Pluripotent Stem Cells for Drug Discovery and Toxicity Assessment
Learn more below.